Is AC Immune Stock a Good Investment?
AC Immune Investment Advice | ACIU |
- Examine AC Immune's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research AC Immune's leadership team and their track record. Good management can help AC Immune navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact AC Immune's business and its evolving consumer preferences.
- Compare AC Immune's performance and market position to its competitors. Analyze how AC Immune is positioned in terms of product offerings, innovation, and market share.
- Check if AC Immune pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about AC Immune's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in AC Immune stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if AC Immune is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine AC Immune Stock
Researching AC Immune's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 22.0% of the company shares are held by company insiders. The book value of AC Immune was presently reported as 1.3. The company recorded a loss per share of 0.45. AC Immune had not issued any dividends in recent years.
To determine if AC Immune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AC Immune's research are outlined below:
| AC Immune had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 14.8 M. Net Loss for the year was (54.23 M) with loss before overhead, payroll, taxes, and interest of (56.4 M). | |
| AC Immune currently holds about 154.15 M in cash with (60.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83. | |
| AC Immune has a frail financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: AC Immune stock jumps 20 percent on data for Parkinsons disease drug - MSN |
AC Immune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AC Immune. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AC Immune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 26th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact AC Immune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises AC Immune's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-11-13 | 2017-09-30 | -0.13 | -0.15 | -0.02 | 15 | ||
2017-08-09 | 2017-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2016-11-11 | 2016-09-30 | -0.16 | -0.18 | -0.02 | 12 | ||
2020-05-04 | 2020-03-31 | -0.14 | -0.11 | 0.03 | 21 | ||
2018-08-08 | 2018-06-30 | -0.22 | -0.19 | 0.03 | 13 | ||
2024-05-13 | 2024-03-31 | -0.14 | -0.18 | -0.04 | 28 | ||
2018-11-13 | 2018-09-30 | -0.25 | -0.21 | 0.04 | 16 | ||
2021-11-08 | 2021-09-30 | -0.27 | -0.22 | 0.05 | 18 |
Know AC Immune's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AC Immune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AC Immune backward and forwards among themselves. AC Immune's institutional investor refers to the entity that pools money to purchase AC Immune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eversept Partners, Llc | 2024-09-30 | 99.3 K | Alps Advisors Inc | 2024-09-30 | 76.6 K | Geode Capital Management, Llc | 2024-09-30 | 58.3 K | Two Sigma Investments Llc | 2024-09-30 | 57.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 57.1 K | Man Group Plc | 2024-09-30 | 27.4 K | Citadel Advisors Llc | 2024-09-30 | 21.8 K | Nomura Holdings Inc | 2024-06-30 | 20 K | Group One Trading, Lp | 2024-06-30 | 19.4 K | Bvf Inc | 2024-09-30 | 19.5 M | Blackrock Inc | 2024-06-30 | 2.6 M |
AC Immune's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 337.4 M.Market Cap |
|
AC Immune's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.34) | (0.35) |
Determining AC Immune's profitability involves analyzing its financial statements and using various financial metrics to determine if AC Immune is a good buy. For example, gross profit margin measures AC Immune's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AC Immune's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in AC Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AC Immune. Check AC Immune's Beneish M Score to see the likelihood of AC Immune's management manipulating its earnings.
Evaluate AC Immune's management efficiency
AC Immune has return on total asset (ROA) of (0.1204) % which means that it has lost $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3116) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Liabilities And Stockholders Equity is likely to gain to about 193.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.90 | 1.70 | |
| Tangible Book Value Per Share | 1.30 | 1.57 | |
| Enterprise Value Over EBITDA | (5.42) | (5.69) | |
| Price Book Value Ratio | 2.22 | 2.11 | |
| Enterprise Value Multiple | (5.42) | (5.69) | |
| Price Fair Value | 2.22 | 2.11 | |
| Enterprise Value | 281 M | 498.1 M |
The operational strategies employed by AC Immune management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.277 |
Basic technical analysis of ACIU Stock
As of the 26th of November, AC Immune owns the Coefficient Of Variation of 1656.72, market risk adjusted performance of 0.2727, and Standard Deviation of 3.6. AC Immune technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices.AC Immune's Outstanding Corporate Bonds
AC Immune issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AC Immune uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ACIU bonds can be classified according to their maturity, which is the date when AC Immune has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand AC Immune's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing AC Immune's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.054 | |||
| Market Risk Adjusted Performance | 0.2727 | |||
| Mean Deviation | 2.54 | |||
| Semi Deviation | 3.07 | |||
| Downside Deviation | 3.25 | |||
| Coefficient Of Variation | 1656.72 | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.95 | |||
| Information Ratio | 0.0246 | |||
| Jensen Alpha | 0.1136 | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | 0.0272 | |||
| Treynor Ratio | 0.2627 | |||
| Maximum Drawdown | 23.56 | |||
| Value At Risk | (4.63) | |||
| Potential Upside | 5.81 | |||
| Downside Variance | 10.58 | |||
| Semi Variance | 9.43 | |||
| Expected Short fall | (2.92) | |||
| Skewness | 0.6447 | |||
| Kurtosis | 3.1 |
| Risk Adjusted Performance | 0.054 | |||
| Market Risk Adjusted Performance | 0.2727 | |||
| Mean Deviation | 2.54 | |||
| Semi Deviation | 3.07 | |||
| Downside Deviation | 3.25 | |||
| Coefficient Of Variation | 1656.72 | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.95 | |||
| Information Ratio | 0.0246 | |||
| Jensen Alpha | 0.1136 | |||
| Total Risk Alpha | (0.35) | |||
| Sortino Ratio | 0.0272 | |||
| Treynor Ratio | 0.2627 | |||
| Maximum Drawdown | 23.56 | |||
| Value At Risk | (4.63) | |||
| Potential Upside | 5.81 | |||
| Downside Variance | 10.58 | |||
| Semi Variance | 9.43 | |||
| Expected Short fall | (2.92) | |||
| Skewness | 0.6447 | |||
| Kurtosis | 3.1 |
Consider AC Immune's intraday indicators
AC Immune intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AC Immune stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 3353.63 | |||
| Daily Balance Of Power | (0.07) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 3.36 | |||
| Day Typical Price | 3.37 | |||
| Price Action Indicator | 0.035 | |||
| Period Momentum Indicator | (0.01) |
AC Immune Corporate Filings
6K | 14th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 26th of July 2024 Other Reports | ViewVerify | |
| 14th of March 2024 Other Reports | ViewVerify | |
13A | 9th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
ACIU Stock media impact
Far too much social signal, news, headlines, and media speculation about AC Immune that are available to investors today. That information is available publicly through ACIU media outlets and privately through word of mouth or via ACIU internal channels. However, regardless of the origin, that massive amount of ACIU data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AC Immune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AC Immune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AC Immune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AC Immune alpha.
AC Immune Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards AC Immune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
AC Immune Corporate Management
| Julian Snow | VP Development | Profile | |
| Nuno MD | Chief Officer | Profile | |
| Christopher Roberts | Interim Fin | Profile | |
| Sonia Poli | Head Science | Profile | |
| Piergiorgio Donati | Chief Officer | Profile | |
| Pr MD | Chief Officer | Profile | |
| Joshua Drumm | Head Relations | Profile |
Already Invested in AC Immune?
The danger of trading AC Immune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AC Immune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AC Immune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AC Immune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.